MPDL3280A (Anti-PD-L1) Treatment Leads to Clinical Activity in Metastatic Bladder Cancer Researchers examined the anti-PD-L1 antibody MPDL3280A, a systemic cancer immunotherapy, for the treatment of metastatic urothelial bladder cancer. This Phase I expansion study, with an adaptive design that allowed for biomarker-positive enriched cohorts, demonstrated that tumors expressing PD-L1-positive tumor-infiltrating immune cells had particularly high response rates. [Nature] Abstract | Press Release PD-1 Blockade Induces Responses by Inhibiting Adaptive Immune Resistance Scientists show that pre-existing CD8+ T cells distinctly located at the invasive tumor margin are associated with expression of the programmed death-1 (PD-1)/PD-1 ligand immune inhibitory axis and may predict response to therapy. [Nature] Abstract | Press Release The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function TIGIT is highly expressed on human and murine tumor-infiltrating T cells, and, in models of both cancer and chronic viral infection, antibody coblockade of TIGIT and PD-L1 synergistically and specifically enhanced CD8+ T cell effector function, resulting in significant tumor and viral clearance, respectively. [Cancer Cell] Abstract | Graphical Abstract Safety and Preliminary Evidence of Biologic Efficacy of a Mammaglobin-A DNA Vaccine in Patients with Stable Metastatic Breast Cancer Fourteen subjects were treated with the mammaglobin-A DNA vaccine and no significant adverse events have been observed. Eight of 14 subjects were HLA-A2+, and the CD8 T-cell response to vaccination was studied in detail. [Clin Cancer Res] Abstract | Press Release Intrathymic Tfh/B Cells Interaction Leads to Ectopic GCs Formation and Anti-AChR Antibody Production: Central Role in Triggering MG Occurrence Researchers aimed to determine whether T follicular helper (Tfh)/B cell interaction exists in myasthenia gravis (MG) thymus and address its role in the ectopic germinal centers (GCs) formation and acetylcholine receptor (AChR) antibody production. [Mol Neurobiol] Abstract The Tol2 Transposon System Mediates the Genetic Engineering of T-Cells with CD19-Specific Chimeric Antigen Receptors for B-Cell Malignancies Scientists used the Tol2 transposon system to stably transfer CD19-specific chimeric antigen receptor into human T-cells. Expanded CD3+ T-cells with stable and high-level transgene expression produced interferon-γ upon stimulation with CD19 and specifically lysed Raji cells, a CD19+ human B-cell lymphoma cell line. [Gene Ther] Abstract Monomethyl Fumarate Augments NK Cell Lysis of Tumor Cells through Degranulation and the Upregulation of NKp46 and CD107a Investigators examined the effects of dimethyl fumarate (DMF) and the DMF metabolite monomethyl fumarate (MMF) on various activities of natural killer (NK) cells. They demonstrate that MMF augments the primary CD56+, but not CD56–, NK cell lysis of K562 and RAJI tumor cells. [Cell Mol Immunol] Abstract Activated Regulatory and Memory T-Cells Accumulate in Malignant Ascites from Ovarian Carcinoma Patients Scientists conducted a detailed characterization of CD4+ T-cells, CD8+ T-cells and regulatory T-cell subsets in the peripheral blood and malignant ascites fluid from seventeen patients with ovarian carcinoma of epithelial origin. [Cancer Immunol Immunother] Abstract Fingolimod Increases CD39-Expressing Regulatory T Cells in Multiple Sclerosis Patients Investigators explored regulatory and inflammatory mechanisms activated in fingolimod treated multiple sclerosis patients. Fingolimod treatment increased mRNA levels of CD39, AHR and CYP1B1 but decreased mRNA expression of IL-17, IL-22 and FOXP3 mRNA in peripheral blood mononuclear cells. [PLoS One] Full Article Subscribe to our sister publications: Immunology of Infectious Disease News and Immune Regulation News! |